Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Articles published by Fulcrum Therapeutics, Inc.

< Previous 1 2 Next >
Fulcrum Therapeutics Announces Recent Business Highlights and Financial Results for First Quarter 2025
From Fulcrum Therapeutics, Inc.
Via GlobeNewswire
Tickers FULC
Fulcrum Therapeutics to Host First Quarter 2025 Financial Results Conference Call and Webcast on Thursday, May 1, 2025, at 8:00 a.m. ET
From Fulcrum Therapeutics, Inc.
Via GlobeNewswire
Tickers FULC
Fulcrum Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Fulcrum Therapeutics, Inc.
Via GlobeNewswire
Tickers FULC
Fulcrum Therapeutics to Participate in the Leerink Partners Global Healthcare Conference
From Fulcrum Therapeutics, Inc.
Via GlobeNewswire
Tickers FULC
Fulcrum Therapeutics Announces Recent Business Highlights and Financial Results for Fourth Quarter and Full Year 2024
From Fulcrum Therapeutics, Inc.
Via GlobeNewswire
Tickers FULC
Fulcrum Therapeutics to Host Fourth Quarter and Full Year 2024 Financial Results Conference Call and Webcast on Tuesday, February 25, 2025, at 8:00 a.m. ET
From Fulcrum Therapeutics, Inc.
Via GlobeNewswire
Tickers FULC
Fulcrum Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Fulcrum Therapeutics, Inc.
Via GlobeNewswire
Tickers FULC
Fulcrum Therapeutics to Participate in the Oppenheimer 35th Annual Healthcare Life Sciences Conference
From Fulcrum Therapeutics, Inc.
Via GlobeNewswire
Tickers FULC
Fulcrum Therapeutics to Participate in Upcoming December Conferences
From Fulcrum Therapeutics, Inc.
Via GlobeNewswire
Tickers FULC
Fulcrum Therapeutics Announces Recent Business Highlights and Financial Results for Third Quarter 2024
From Fulcrum Therapeutics, Inc.
Via GlobeNewswire
Tickers FULC
Fulcrum Therapeutics to Participate in the Stifel Healthcare Conference
From Fulcrum Therapeutics, Inc.
Via GlobeNewswire
Tickers FULC
Fulcrum Therapeutics to Host Third Quarter 2024 Financial Results Conference Call and Webcast on Wednesday, November 13, 2024 at 8:00 a.m. ET
From Fulcrum Therapeutics, Inc.
Via GlobeNewswire
Tickers FULC
Fulcrum Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Fulcrum Therapeutics, Inc.
Via GlobeNewswire
Tickers FULC
Fulcrum Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Fulcrum Therapeutics, Inc.
Via GlobeNewswire
Tickers FULC
Fulcrum Therapeutics Announces Topline Results from Phase 3 REACH Clinical Trial of Losmapimod in Facioscapulohumeral Muscular Dystrophy (FSHD)
From Fulcrum Therapeutics, Inc.
Via GlobeNewswire
Tickers FULC
Fulcrum Therapeutics to Participate in Upcoming September Conferences
From Fulcrum Therapeutics, Inc.
Via GlobeNewswire
Tickers FULC
Fulcrum Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Fulcrum Therapeutics, Inc.
Via GlobeNewswire
Tickers FULC
Fulcrum Therapeutics Strengthens Leadership Team with the Appointments of Isabel Kalofonos as Chief Commercial Officer and Heather Faulds as Chief Regulatory Affairs & Quality Assurance Officer
From Fulcrum Therapeutics, Inc.
Via GlobeNewswire
Tickers FULC
Fulcrum Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Fulcrum Therapeutics, Inc.
Via GlobeNewswire
Tickers FULC
Fulcrum Therapeutics Announces Recent Business Highlights and Financial Results for Second Quarter 2024
From Fulcrum Therapeutics, Inc.
Via GlobeNewswire
Tickers FULC
Fulcrum Therapeutics to Host Second Quarter 2024 Financial Results Conference Call and Webcast on Wednesday, July 31, 2024, at 8:00 a.m. ET
From Fulcrum Therapeutics, Inc.
Via GlobeNewswire
Tickers FULC
Fulcrum Therapeutics to Present at the 31st Annual FSHD Society International Research Congress
From Fulcrum Therapeutics, Inc.
Via GlobeNewswire
Tickers FULC
Fulcrum Therapeutics to Participate in the Goldman Sachs’ 45th Annual Global Healthcare Conference
From Fulcrum Therapeutics, Inc.
Via GlobeNewswire
Tickers FULC
Fulcrum Therapeutics Announces Recent Business Highlights and Financial Results for First Quarter 2024
From Fulcrum Therapeutics, Inc.
Via GlobeNewswire
Tickers FULC SNY
Fulcrum Therapeutics Enters into a Collaboration and License Agreement with Sanofi for the Development and Commercialization of Losmapimod in Facioscapulohumeral Muscular Dystrophy
From Fulcrum Therapeutics, Inc.
Via GlobeNewswire
Tickers FULC SNY
Fulcrum Therapeutics to Participate in Upcoming May Conferences
From Fulcrum Therapeutics, Inc.
Via GlobeNewswire
Tickers FULC
Fulcrum Therapeutics Announces Publication of Results from Phase 2b Clinical Trial of Losmapimod in Facioscapulohumeral muscular dystrophy (ReDUX4) in The Lancet Neurology
From Fulcrum Therapeutics, Inc.
Via GlobeNewswire
Tickers FULC
Fulcrum Therapeutics to Host First Quarter 2024 Financial Results Conference Call and Webcast on Monday, May 13, 2024, at 8:00 a.m. ET
From Fulcrum Therapeutics, Inc.
Via GlobeNewswire
Tickers FULC
Fulcrum Therapeutics to Participate at the Cantor Virtual Muscular Dystrophy Symposium
From Fulcrum Therapeutics, Inc.
Via GlobeNewswire
Tickers FULC
Fulcrum Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Fulcrum Therapeutics, Inc.
Via GlobeNewswire
Tickers FULC
< Previous 1 2 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.